The FIGO Stage IVA Versus IVB of Ovarian Cancer: Prognostic Value and Predictive Value for Neoadjuvant Chemotherapy
Conclusions
The reclassification of FIGO stage IV into stage IVA or IVB was not prognostic as expected. Compared with stage IVA patients, stage IVB patients have a better overall survival and may benefit more from NACT.
Source: International Journal of Gynecological Cancer - Category: Cancer & Oncology Tags: Ovarian Cancer Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Cytology | Epithelial Cancer | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | OBGYN | Ovarian Cancer | Ovaries